Business ❯ Pharmaceutical Industry ❯ Market Competition

Drug Pricing

Novo Nordisk Eli Lilly Generic Medications Consumer Access Merck Cost Analysis Insurance Coverage Patent Expiration Consumer Health Weight Loss Solutions Compounded Drugs Access to Medication Novo Nordisk's Semaglutide Emerging Therapies Patent Issues Sales Performance Market Dominance Cost-Effectiveness Biosimilars Investor Confidence Psoriasis Medications Generic Drugs Generic Drug Launches Innovation Strategies Semaglutide

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

The once-daily peptide offers biologic-like efficacy without injections.

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA OKs RVO Use and Monthly Dosing for Regeneron’s Eylea HD

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

FDA Approves Keytruda QLEX, a Rapid Subcutaneous Option for Most Adult Solid Tumor Uses